We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00734864
Recruitment Status : Withdrawn (Study drug supplier withdrew support for the study. Study was withdrawn from the Duke IRB.)
First Posted : August 14, 2008
Last Update Posted : November 21, 2012
Bristol-Myers Squibb
Information provided by (Responsible Party):
Annick Desjardins, Duke University Medical Center

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Estimated Primary Completion Date : June 2010
  Estimated Study Completion Date : June 2012